Search results
AstraZeneca (LON:AZN) Rating Reiterated by JPMorgan Chase & Co.
ETF DAILY NEWS· 4 days agoAstraZeneca (LON:AZN – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at JPMorgan Chase & Co. in a research report issued to ...
AstraZeneca Admits Covishield Vaccine Can Cause Rare Side Effects, What Is TTS?
Homenewshere.com· 5 days agoAstraZeneca has acknowledged that its Covid vaccine, Covishield, can cause a rare side effect called...
AstraZeneca Targets $80B Revenue by 2030 Through Pipeline Expansion
Market Watch· 6 days agoBy Helena Smolak AstraZeneca has set out a target to grow revenue to $80 billion by 2030 as it aims to bolster its investment in technologies and platforms....
AstraZeneca joins obesity biotech SixPeaks at basecamp with $80M for buyout option
FierceBiotech· 5 days agoThe obesity business is cutthroat these days. AstraZeneca is taking no chances on missing out on the...
AstraZeneca aims increase its annual revenue by 75% in its post-COVID era
Quartz· 6 days agoCambridge, U.K.-based pharmacuetical giant AstraZeneca announced an ambitious sales goal for the end of this decade, just as it pulls it COVID-19 vaccines off the shelves.
How to get a degree for free
The Telegraph via Yahoo Finance· 7 hours agoIt’s not just the NHS who are signed up to degree apprenticeships. Large companies such as Coca-Cola, Barclays, IBM, and AstraZeneca offer degree...
AstraZeneca’s fasenra asthma drug shows promise for COPD treatment
BioPharma-Reporter· 6 days agoThis approval extends Fasenra's availability to over 80 countries, including the US, EU, and Japan....
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient...
Benzinga· 7 days agoSunday, Amgen Inc AMGN and AstraZeneca Plc AZN announced the results of the Phase 2a COURSE trial of...
AstraZeneca pays $19M to Harbour BioMed's Nona for preclinical cancer antibodies
FierceBiotech· 4 days agoDays after AstraZeneca set out how new oncology drugs would help fuel its “bold” ambition to almost double its revenue by the end of the decade, the Big Pharma has further ...
AstraZeneca Aims for $80 Billion in Sales by 2030
Bloomberg· 6 days agoHave a confidential tip for our reporters? AstraZeneca Plc aims to almost double sales to $80 billion by 2030 as Chief Executive Officer Pascal Soriot...
